1576-45-0

Usage

Uses

Used in Pharmaceutical Industry:
Benzoic acid, 3-[(phenylamino)sulfonyl]is used as an intermediate in the synthesis of various pharmaceuticals. Its unique chemical structure allows it to be a key component in the development of new drugs and medications.
Used in Dye Industry:
Benzoic acid, 3-[(phenylamino)sulfonyl]is utilized in the production of dyes due to its ability to impart color to various materials. Its chemical properties make it suitable for creating a wide range of hues and shades.
Used in Polymer and Plastics Manufacturing:
Benzoic acid, 3-[(phenylamino)sulfonyl]is employed in the manufacturing of polymers and plastics, where it contributes to the properties of the final products, such as strength, flexibility, and durability.
Used in Cosmetics and Personal Care Products:
Due to its antifungal and antibacterial properties, Benzoic acid, 3-[(phenylamino)sulfonyl]is commonly used as a preservative in cosmetics and personal care products. It helps maintain the freshness and quality of these products by preventing the growth of harmful microorganisms.
Used in Food and Beverage Industry:
Benzoic acid, 3-[(phenylamino)sulfonyl]is used as a preservative in food and beverages to extend their shelf life and prevent spoilage. Its ability to inhibit the growth of bacteria and fungi ensures the safety and quality of various food products.
Used in Organic Compound Synthesis:
As an intermediate, Benzoic acid, 3-[(phenylamino)sulfonyl]plays a crucial role in the synthesis of various organic compounds. Its unique structure allows for the creation of a wide range of chemical entities with diverse applications across different industries.

Upstream product

• 4025-64-3 3-Carboxybenzenesulfonyl chloride 
• 65-85-0 benzoic acid 
• 100-52-7 benzaldehyde 
• 62-53-3 aniline 
• 110-86-1 pyridine 
• 60-29-7 diethyl ether 
• 405058-55-1 3-formyl-N-phenylbenzene-1-sulfonamide 

Downstream Products

• 866323-87-7 (2E)-3-{3-[(phenylamino)sulfonyl]phenyl}prop-2-enoic acid 
• 866323-14-0 belinostat 
• 405058-54-0 3-(hydroxymethyl)-N-phenylbenzenesulfonamide 
• 405058-55-1 3-formyl-N-phenylbenzene-1-sulfonamide 
• 38461-47-1 N-phenyl-3-(phenylsulfamoyl)benzamide 
• 866324-02-9 methyl 3-[(phenylamino)sulfonyl]benzenecarboxylate 

Relevant academic research and scientific papers

Design and synthesis of newer N-benzimidazol-2yl benzamide analogues as allosteric activators of human glucokinase

Allosteric activators of human glucokinase (GK) had revealed significant hypoglycemic effects for therapy of type-2 diabetes (T2D) in animal as well as human models. Some newer N-benzimidazol-2yl substituted benzamide analogues were prepared and assessed for activation of GK accompanied by molecular docking investigations for predicting the bonding interactions of these derivatives with the residues in allosteric site of GK protein. Amongst the derivatives synthesized, compounds 2 and 7 strongly increased catalytic action of GK (GK activation fold >2.0 in comparison to control) in vitro. The results of in-vitro testing were supported by the molecular docking investigations of these analogues with GK protein’s allosteric site residues (showed appreciable H-bond interactions with Arg63 residue of GK). Derivatives investigated in present study afforded few lead compounds for the discovery of harmless and strong allosteric GK activating compounds for treating T2D.

Synthesis,docking and evaluation of phenylacetic acid and trifluoro-methylphenyl substituted benzamide derivatives as potential ppar? agonists

Background: Peroxisome proliferator-activated receptor (PPAR) ? is a type of PPARs belonging to the steroid or nuclear hormone receptor super family. Activation of PPAR? leads to metabolism of fat instead of glucose by body for energy requirements. PPAR? represent an emerging pharmacological target for the treatment of metabolic syndrome (MS). Many selective and potent PPAR? agonists had been synthesized with a potential role in the treatment of various disorders associated with MS including type 2 diabetes and inflammation. Objective: The present work was designed to synthesize and evaluate the antidiabetic and anti-inflammatory activity of some newer phenylacetic acid and trifluoromethylphenyl substituted benzamide derivatives as potential PPAR? agonists. Methods: This work involved the synthesis of newer sulfamoyl benzamide derivatives and their evaluation by molecular docking studies to determine the binding interactions for the best fit conformations in the binding site of the PPAR? protein. Based on the results of the in silico studies, the selected compounds were tested for their antidiabetic and anti-inflammatory activity in the animal models. Results: Amongst the synthesized molecules, compound 7 showed higher anti-diabetic activity and compound 19 showed higher anti-inflammatory activity. The experimental results were found to be in concordance with that of the in silico results. Most of the synthesized molecules were found to have drug like properties as devised by Lipinski's rule of five. Conclusion: These molecules can act as the starting hits for the design of safe, effective and bioavailable PPAR? agonists for the potential treatment of MS and related diseases.

Synthesis method of belinostat

The invention discloses a synthesis method of belinostat. The method comprises the following steps: by using benzoic acid as an initial material, performing six reaction steps of chlorosulfonation, aniline condensation, reduction, oxidation, Witting-Horner condensation and hydrolysis, acylating chlorination and hydroxylamine condensation to prepare a target compound. The initial material benzoic acid of the method is cheap and easy to obtain, the sulfonylation and acylating chlorination reaction are realized through one step, the preparation time is shortened, and the yield is improved. In the oxidation process, an oxidizing reagent which is cheap and does not contains metal ion is adopted so that the active ingredients easily achieve the requirement of heavy metal ion limitation, and the pollution to the environment is reduced. All reaction intermediates of the method are solid and can be purified through a salt formation or recrystallization method, the time-consuming and labor-consuming column chromatography purification is avoided, and the method is suitable for industrial production.

Synthesis and biological evaluation of novel (E)-N′-(2,3-dihydro-1H-inden-1-ylidene) benzohydrazides as potent LSD1 inhibitors

Lysine specific demethylase 1 (LSD1) plays an important role in regulating histone lysine methylation at residues K4 and K9 on histone H3 and is recognized as an attractive therapeutic target in multiple malignancies. In this study, a series of novel (E)-N′-(2,3-dihydro-1H-inden-1-ylidene) benzohydrazides were synthesized and biologically evaluated for their potential LSD1 inhibitory effect. Among them, compounds 5a and 5n showed the most potent LSD1 inhibitory activity with IC50values of 1.4 and 1.7?nM, respectively, which were about 10 times more potent compared with (E)-N-(1-(5-chloro-2-hydroxyphenyl) ethylidene)-3-(morpholinosulf-only) benzohydrazide (J. Med. Chem. 2013, 56, 9496–9508; as reference compound). Compounds 5a and 5n also exhibited marked anti-proliferation activities against cancer cell lines that highly expressed LSD1. These results suggest that these optimized compounds might be served as promising LSD1 inhibitors against cancer, which merit further study.

Synthesis, docking and antidiabetic activity of some newer benzamide derivatives as potential glucokinase activators

Background: Glucokinase activators (GKAs) are the new class of candidate drugs which act on glucokinase (GK) enzyme and show their hypoglycaemic activity. Objective: The present work was planned to synthesize and evaluate the antidiabetic activity of a series of newer benzamide derivatives as potential GKAs. Method: This work involved synthesis of newer benzamide derivatives from benzoic acid and their evaluation by docking studies to determine the binding interactions for the best fit conformations in the binding site of GK enzyme. Based on the results of docking studies, the selected molecules were tested for their antidiabetic activity in the animal model. Results: Amongst the synthesized molecules, compounds 14 and 20 with phenyl-substituted thiazole moiety on amide nitrogen, exhibited highest activity in vivo. The results of the in vivo antidiabetic studies were found to be consistent with those of docking studies. Conclusion: These newly synthesized molecules thus can be treated as the initial hits for the development of new, safe, effective and orally bioavailable GKAs as therapeutic agents for the treatment of diabetic disorders.

Novel sulfonamide derivatives as inhibitors of histone deacetylase

Inhibition of the enzyme histone deacetylase (HDAC) is emerging as a novel approach to the treatment of cancer. A series of novel sulfonamide derivatives were synthesized and evaluated for their ability to inhibit human HDAC. Compounds were identified which are potent enzyme inhibitors, with IC 50 values in the low nanomolar range against enzyme obtained from HeLa cell extracts, and with antiproliferative effects in cell culture. Extensive characterization of the structure - activity relationships of this series identified key requirements for activity. These include the direction of the sulfonamide bond and substitution patterns on the central phenyl ring. The alkyl spacer between the aromatic head group and the sulfonamide functionality also influenced the HDAC inhibitory activity. One of these compounds, m11.1, also designated PXD101, has entered clinical trials for solid tumors and haematological malignancies.

CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS

Tertiary amines containing a multiplicity of heteroaromatic substituents are useful as chemokine receptor modulators.